U.S.-listed shares of Danish drugmaker Novo Nordisk rise 6% premarket.
The UK health regulator has approved a higher 7.2 mg weekly dose of Novo's Wegovy for obesity patients.
Newer studies found the 7.2 mg dose can achieve around 20% weight loss.
The new dose is given as three separate injections and exceeds the previous 2.4 mg limit.
NVO fell ~42% in 2025.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.